For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
In Abcam’s TACE inhibitor screening Kit, TACE (tumor necrosis factor-a-converting enzyme) hydrolyzes the specific FRET substrate to release the quenched fluorescent group, which can be detected fluorometrically at Ex/Em = 318/449 nm. In the presence of the potent TACE inhibitor, the hydrolyzation of substrate will be impeded. The kit provides a rapid, simple, sensitive and reliable test suitable for high-throughput screening of TACE inhibitors and can be modified to check the relative TACE activity. Inhibitor Control GM6001 is included to compare the efficacy of test inhibitors.
The TACE (tumor necrosis factor-a-converting enzyme), also called ADAM metallopeptidase domain 17 (ADAM17), is a 70-kDa enzyme that belongs to the ADAM protein family of disintegrins and metalloproteases. TACE is believed to be involved in the processing of tumor necrosis factor alpha (TNF-a) at the surface of the cell, and from within the intracellular membranes of the trans-Golgi network. This process, which is also known as 'shedding', involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-a), and is of known physiological importance.
|TACE Assay Buffer||WM||1 x 25ml|
|TACE Enzyme||Green||1 vial|
|TACE Inhibitor Control||Purple||1 x 20µl|
|TACE Substrate||Red||1 x 0.2ml|
Our Abpromise guarantee covers the use of ab155889 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent concentration.|
ab155889 has not yet been referenced specifically in any publications.